- Record: found
- Abstract: not found
- Article: not found
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Michael S. Hofman
1
,
2 ,
Louise Emmett
2
,
3 ,
John Violet
1
,
2 ,
Alison Y. Zhang
2
,
4 ,
Nicola J. Lawrence
2
,
4 ,
Martin Stockler
2
,
4 ,
Roslyn J. Francis
5
,
6 ,
Amir Iravani
1 ,
Scott Williams
1
,
2 ,
Arun Azad
1
,
2 ,
Andrew Martin
2
,
4 ,
Margaret McJannett
2 ,
Ian D. Davis
2
,
7
,
8 ,
ANZUP TheraP team
October 22 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity
to prostate-specific membrane antigen (PSMA), in men with metastatic castration-resistant
prostate cancer (mCRPC) who have received prior docetaxel treatment.